Drugs / OXYNORM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05114265 | Feb → Oct 2022 | — | Kures, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT05821517 Comparator | Dec 2023 → Dec 2026 expected | — | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| — | NCT02094807 Background | Apr 2014 → May 2020 | — | Sahlgrenska University Hospital | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OXYNORM | “An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating...” NCT05821517 ↗ |
| Route | Oral | “Single oral dose of OxyNorm” NCT05114265 ↗ |